ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04065269

Recruitment Status : Unknown

Verified September 2020 by Institute of Cancer Research, United Kingdom.
Recruitment status was: Recruiting

First Posted : August 22, 2019

Last Update Posted : September 3, 2020

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Cancer Research UK

AstraZeneca

Information provided by (Responsible Party):

Institute of Cancer Research, United Kingdom

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	March 2023
Estimated Study Completion Date :	March 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Smith G, Alholm Z, Coleman RL, Monk BJ. DNA Damage Repair Inhibitors-Combination Therapies. Cancer J. 2021 Nov-Dec 01;27(6):501-505. doi: 10.1097/PPO.0000000000000561.

To Top